Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey

Objectives To investigate German physicians’ attitudes towards and experiences with voluntary disclosure of payments by pharmaceutical companies in a public database and their impact on future decisions for or against disclosure.Design A national cross-sectional survey conducted in 2018 among physic...

Full description

Saved in:
Bibliographic Details
Main Authors: Marlene Stoll, Lara Hubenschmid, Cora Koch, Klaus Lieb, Boris Egloff
Format: Article
Language:English
Published: BMJ Publishing Group 2022-06-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/6/e055963.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832583987521912832
author Marlene Stoll
Lara Hubenschmid
Cora Koch
Klaus Lieb
Boris Egloff
author_facet Marlene Stoll
Lara Hubenschmid
Cora Koch
Klaus Lieb
Boris Egloff
author_sort Marlene Stoll
collection DOAJ
description Objectives To investigate German physicians’ attitudes towards and experiences with voluntary disclosure of payments by pharmaceutical companies in a public database and their impact on future decisions for or against disclosure.Design A national cross-sectional survey conducted in 2018 among physicians who voluntarily disclosed at least one payment in the German transparency regulation.Setting Retrospective paper-pencil questionnaire about attitudes towards and experiences with voluntary payment disclosures in the first (2015) and second (2016) years of the German transparency regulation.Participants German physicians who disclosed either in the first year only, the second year only, or in both years of the transparency regulation.Primary outcomes (1) The probability to disclose in 2016, predicted by physicians’ experience of reactions from others in 2015, descriptive norms and attitudes towards transparency; (2) Frequency and (3) Content of reactions from others in 2015 compared with 2016.Results Data of 234 respondents were analysed (n=42, 45 and 147 physicians who disclosed in 2015, 2016 or both years, respectively). The probability to disclose in 2016 was not predicted by perceived reactions, norms or attitudes towards transparency (p>0.01). Most participants reported not to have received any reactions by patients (190/234, 81%), colleagues (128/234, 55%) or the private environment (153/234, 65%). Neither frequency nor content of reactions differed between the first and second years (scale 1–5; frequency: Mdn2015,2016 = 1.33 vs 1.00, rb=−0.17, p>0.01; content: Mdn2015,2016 = 3.00 vs 3.00, rb=0.19, p>0.01). However, media reporting, fear of reputational damage and a feeling of being defamed were mentioned as reasons for non-disclosure.Conclusions While confirmatory analyses did not provide significant results, descriptive analyses showed that participants who voluntarily disclose payments mainly do not experience any reactions towards their disclosures but report fears about losing their reputation due to disclosures.
format Article
id doaj-art-86c4dc25299144528db3a7a4265684a6
institution Kabale University
issn 2044-6055
language English
publishDate 2022-06-01
publisher BMJ Publishing Group
record_format Article
series BMJ Open
spelling doaj-art-86c4dc25299144528db3a7a4265684a62025-01-28T00:05:12ZengBMJ Publishing GroupBMJ Open2044-60552022-06-0112610.1136/bmjopen-2021-055963Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional surveyMarlene Stoll0Lara Hubenschmid1Cora Koch2Klaus Lieb3Boris Egloff4Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, GermanyLeibniz Institute for Resilience Research (LIR) gGmbH, Mainz, GermanyDepartment of Neurology and Neurophysiology, Medical Center - University of Freiburg, Freiburg, GermanyPsychiatry and Psychotherapy, University Medical Center Mainz, Mainz, GermanyDepartment of Psychology, Johannes Gutenberg University Mainz, Mainz, GermanyObjectives To investigate German physicians’ attitudes towards and experiences with voluntary disclosure of payments by pharmaceutical companies in a public database and their impact on future decisions for or against disclosure.Design A national cross-sectional survey conducted in 2018 among physicians who voluntarily disclosed at least one payment in the German transparency regulation.Setting Retrospective paper-pencil questionnaire about attitudes towards and experiences with voluntary payment disclosures in the first (2015) and second (2016) years of the German transparency regulation.Participants German physicians who disclosed either in the first year only, the second year only, or in both years of the transparency regulation.Primary outcomes (1) The probability to disclose in 2016, predicted by physicians’ experience of reactions from others in 2015, descriptive norms and attitudes towards transparency; (2) Frequency and (3) Content of reactions from others in 2015 compared with 2016.Results Data of 234 respondents were analysed (n=42, 45 and 147 physicians who disclosed in 2015, 2016 or both years, respectively). The probability to disclose in 2016 was not predicted by perceived reactions, norms or attitudes towards transparency (p>0.01). Most participants reported not to have received any reactions by patients (190/234, 81%), colleagues (128/234, 55%) or the private environment (153/234, 65%). Neither frequency nor content of reactions differed between the first and second years (scale 1–5; frequency: Mdn2015,2016 = 1.33 vs 1.00, rb=−0.17, p>0.01; content: Mdn2015,2016 = 3.00 vs 3.00, rb=0.19, p>0.01). However, media reporting, fear of reputational damage and a feeling of being defamed were mentioned as reasons for non-disclosure.Conclusions While confirmatory analyses did not provide significant results, descriptive analyses showed that participants who voluntarily disclose payments mainly do not experience any reactions towards their disclosures but report fears about losing their reputation due to disclosures.https://bmjopen.bmj.com/content/12/6/e055963.full
spellingShingle Marlene Stoll
Lara Hubenschmid
Cora Koch
Klaus Lieb
Boris Egloff
Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
BMJ Open
title Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
title_full Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
title_fullStr Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
title_full_unstemmed Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
title_short Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
title_sort physicians attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database a cross sectional survey
url https://bmjopen.bmj.com/content/12/6/e055963.full
work_keys_str_mv AT marlenestoll physiciansattitudestowardsdisclosureofpaymentsfrompharmaceuticalcompaniesinanationwidevoluntarytransparencydatabaseacrosssectionalsurvey
AT larahubenschmid physiciansattitudestowardsdisclosureofpaymentsfrompharmaceuticalcompaniesinanationwidevoluntarytransparencydatabaseacrosssectionalsurvey
AT corakoch physiciansattitudestowardsdisclosureofpaymentsfrompharmaceuticalcompaniesinanationwidevoluntarytransparencydatabaseacrosssectionalsurvey
AT klauslieb physiciansattitudestowardsdisclosureofpaymentsfrompharmaceuticalcompaniesinanationwidevoluntarytransparencydatabaseacrosssectionalsurvey
AT borisegloff physiciansattitudestowardsdisclosureofpaymentsfrompharmaceuticalcompaniesinanationwidevoluntarytransparencydatabaseacrosssectionalsurvey